A phase 3b trial examining Eli Lilly’s (LLY) Taltz (ixekizumab) along with Zepbound (tirzepatide) led to positive outcomes in terms of psoriatic arthritis improvement and weight reduction.
At 36 weeks, 31.7% of patients in the TOGETHER-PsA open-label study taking both medicines saw a 50% improvement in psoriatic arthritis activity based on ACR50 as well as ≥10% weight reduction with Taltz and Zepbound compared to only 0.8% on Taltz alone.
Also, 33.5% on the combo treatment achieved ACR50 compared to 20.4% on Taltz monotherapy, meeting a secondary endpoint.
Lilly noted that ~65% of adults with PsA in the U.S. are also obese or overweight with at least one other weight-related comorbidity.
Taltz is an IL-17A antagonist, while Zepbound is a dual GIP/GLP-1 receptor agonist.
